Children Vaccination From 11 to 14 Years Old
QUALIOPIVAC
Qualitative Study Evaluating Opinions Regarding HPV Vaccinnation in Boys' Parents Aged From 11 to 14 Years Old
2 other identifiers
observational
18
1 country
1
Brief Summary
The human papilloma virus infection is the most frequent sexually transmitted infection around the world. In the vast majority of cases, these are inapparent infections that disappear spontaneously. In some cases, the HPV infection persists and can generate anogenital warts or cancer. In France, the papillomavirus is responsible for 6000 new cases of cancer/year with several possible localizations : cervical, anal, penile, oropharyngeal, vulvar or vaginal. Among them, 4580 new cases of cancer/year occur in women, and half of them are diagnosis of cervical cancer. A quarter of cancers caused by papillomavirus occur in men. In France, the commercialization of anti-HPV vaccine in 2007 was addressed only to girls, in order to gain a group immunity that would therefore protect the boys. This vaccination did not achieve the cover immunization target that were announced: the objective was fixed at 60% of vaccination coverage and at the end of 2018, only 24% was achieved on the complete vaccination schedule. In December 2019, the French National Authority for Health recommended the anti-HPV vaccinations in girls and boys.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 29, 2021
CompletedStudy Start
First participant enrolled
May 1, 2021
CompletedFirst Posted
Study publicly available on registry
May 4, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 11, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
February 11, 2022
CompletedApril 22, 2022
April 1, 2022
10 months
April 29, 2021
April 21, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evaluation of knowledge and understanding of papillomavirus and opinions related to anti-HPV vaccination
4 months
Secondary Outcomes (1)
Concept identification to ameliorate the vaccination coverage by overcoming the obstacles
4 months
Interventions
Individual semi-structured interviews
Eligibility Criteria
Patients followed-up by a general practitioner that participate in the study
You may qualify if:
- parents having boys between 11 and 14 years old, followed-up by a general practitioner that participate in the study
- signed inform consent form
You may not qualify if:
- language barrier that could prevent the understanding or formulation of opinions during the interview
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CH Eure-Seine
Évreux, 27015, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 29, 2021
First Posted
May 4, 2021
Study Start
May 1, 2021
Primary Completion
February 11, 2022
Study Completion
February 11, 2022
Last Updated
April 22, 2022
Record last verified: 2022-04